



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **May 2023**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant 's Name into English)

**13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

[99.1 Evogene Investor Presentation.](#)

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.

(Registrant)

Date: May 18, 2023

By: /s/ Yaron Eldad

Yaron Eldad

Chief Financial Officer



INVESTOR PRESENTATION

Ofer Haviv, President & CEO
May 18, 2023

DECODING BIOLOGY

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Agenda

- ✦ **About Evogene**
- ✦ Business model
- ✦ Product-oriented subsidiaries
- ✦ Summary

Annex I - Financial Fundamentals





OUR VISION

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.

DECODING BIOLOGY

Life-science product development

Low probability of success with high cost and long time-to-market

Pharma
Industry



**Cost of developing a single
pharmaceutical drug**

In the 1970's

\$180 million

In recent years

>\$2 billion

Ag-chemicals
Industry




**Years to develop a new crop
protection product**

1995	2000	2005-8	2010-15
8	9	10	11+

*<https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/?sh=7533aa82d459>; Phillips McDougall, 2016.

Life-science product development

The ultimate case of finding “the needle in the haystack”



The challenge: Finding the winning candidates out of a **vast number of possible prospects** that address **a complex myriad of criteria**, to reach successful products



PHARMA &
WELLNESS

AGRICULTURE &
FOOD

OTHER
INDUSTRIES

evogene

The opportunity

Utilizing an **advanced computational biology platform**

To identify the most promising candidates addressing multiple development challenges towards successful life-science products

- **Increase probability of success**
- **Reduce time and cost**


Biology meets disruptive technologies

CPB[★] platform

Incorporates **deep scientific understanding** together with **big data** and advanced **AI** technologies, to successfully discover & guide the **development of novel life-science based products**.

CPB[★] – Computational Predictive Biology


evogene



Tailor-made Tech Engines

The CPB platform enhances product discovery and development through dedicated **Technology Engines** for products based on three core components:

- **Microbes**
- **Small molecules**
- **Genetic elements**




Tech Engines accelerating product discovery & development

✦ Discovery


Computational selection of the most promising candidates to initiate the product development process.

✦ Development

Computational driven solution addressing optimization development challenges for the selected candidates, without impairing their ability to address other product attributes, supporting the way to **successful commercialization**.



Example of Tech Engine User-enabled software dashboard



'Ecosystem' – Potential Markets for MicroBoost AI



Building an
'Ecosystem'
around our tech
engines


Computational Biology Peer Companies

Company	 evogene <small>DECODING BIOLOGY</small>	 GINKGO BIOWORKS	 Schrödinger	 Exscientia	 RELAY <small>THERAPEUTICS</small>
Ticker (NASDAQ)	EVGN	DNA	SDGR	EXAI	RLAY


Agenda

- ✦ About Evogene
- ✦ **Business model**
- ✦ Product-oriented subsidiaries
- ✦ Summary

Annex I - Financial Fundamentals



Evogene's Tech Engines – Potential Addressable Markets



Business Model



evogene

1

Product-oriented subsidiaries powered by Evogene's technology

Establish independent entities focusing on a defined commercial field with a license to use Evogene's unique solutions for product development

Subsidiaries:



Licensed to use **Evogene's tech engines:**



Business Model

2


Collaborations powered by Evogene's technology for the development of innovative products

Joint development with leading companies for defined products utilizing Evogene's unique solution. Typically, partner leads later-stage development and product commercialization.

Powered by **Evogene's tech engines:**




Evogene's Tech Engines – Current Utilization



Agenda

- ✦ About Evogene
- ✦ Business model
- ✦ **Product-oriented subsidiaries**
- ✦ Summary

Annex I - Financial Fundamentals



Product-oriented subsidiaries



evogene
DECODING BIOLOGY



76%*

Microbiome-based Therapeutics

- Immuno-oncology
- GI- related disorders



\$20M investment led by SHC (Apr. 2023)



70%*

Ag Biologicals

- Bio-stimulants
- Bio-pesticides



\$27M investment (Aug 2019)**



\$10M SAFE investment (Aug 2022)



98%*

Ag Chemicals

- Herbicides
- Fungicides
- Insecticides



100%*

Medical Cannabis

- High yield & consumer traits
- Therapeutic traits – currently inflammation & pain



100%*

Castor Cultivation End-to-End Solution

- Elite castor varieties
- Cultivation protocols
- Harvesting and dehulling machinery customized to Casterra's varieties

*Evogene holdings

**Includes \$10M cash investment along with transfer of assets

evogene

DECODING BIOLOGY

20

Mission:

Discovery and development of novel therapies for microbiome-related human disorders using computational biology

Products & Pipeline



Immuno-oncology program

- Combination therapy for cancer with checkpoint inhibitors
- Phase 1 clinical stage
- Addressable market of \$309.7B (by 2030*)



GI related disorders

- Inflammatory Bowel Disorder (IBD) – pre-clinical stage
- Irritable Bowel Syndrome (IBS) – discovery stage
- Addressable market: IBD \$27B; IBS \$3.3B (by 2026**)



Antimicrobial resistance (AMR)

- Clostridium Difficile Infection (CDI) – discovery stage
- Methicillin-resistant Staphylococcus aureus (MRSA) – discovery stage
- Addressable market: CDI \$1.7B (**); MRSA \$1.3B (by 2026****)

Expected upcoming value drivers

Immuno-oncology

- Readout & completion of POC from first in-human study; Pre-IND meeting with FDA

IBD

- Clinical batch production of drug candidate for IBD as preparation for Phase 1 clinical trials in USA.

IBS

- Advancement of pre-clinical studies

*<https://www.alliedmarketresearch.com/cancer-immunotherapy-market>

**https://www.grandviewresearch.com/press-release/global-inflammatory-bowel-disease-ibd-treatment-market?utm_source=blog.goo.ne.jp&utm_medium=referral&utm_campaign=Vrushali_7Aug_hc_InflammatoryBowelDiseaseTreatmentMarket_pr&utm_content=Content; <https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market#:~:text=Report%20Overview,4.4%25%20from%202018%20to%202026>, <https://www.bloomberq.com/press-releases/2019-07-23/ibs-treatment-market-size-worth-3-3-billion-by-2026-caar-10-1-grand-view-research-inc>

*** <https://www.globaldata.com/media/press-release/global-clostridium-difficile-infections-market-approach-1-7-billion-2026/>

**** <https://www.biospace.com/article/releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-surpass-us-1-3-billion-by-2026/>

Example Results:

Immuno-Oncology program – **BMC128**
potentiate the effect of anti-PD-1 therapy
(immunotherapy) in-vivo



Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone

Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug

JULY 26, 2022

Biomica Announces Closing of \$20 Million Financing Round led by Shanghai Healthcare Capital

APRIL 27, 2023



Mission:

Improve food quality, sustainability & agriculture productivity through microbiome based ag-biologicals technology & products

Products & pipeline (examples)

Bio-stimulants



- *Thrivus*TM – primarily spring wheat: commercial stage; addressable USA & Canada markets ~25M acres*
- Bio-stimulants #2 – primarily soy: pre-development stage; addressable market ~90M acres*

Bio-pesticides



- Fruit rots – primarily grapes: pre-commercial; addressable market >\$1B**
- Downy Mildew – fruits and vegetables; development stage 1; addressable market >\$500M**
- Seedling disease – corn and soy: pre-development; addressable market >\$500M**

Expected upcoming value drivers

Bio-stimulants

- *Thrivus*TM – distribution licensing agreements and sales expansion in USA & Canada. Expansion to additional crops and an additional territory by 2025

Bio-pesticides:

- Licensing agreement for Lavie Bio's bio-fungicide candidate for fruit rots (LAV311) – to be finalized during 2023
- Submission for Lavie Bio's bio-fungicide candidate for downy mildew (LAV321) to the US EPA for regulatory approval – expected by 2024
- Co-development and licensing agreement for an additional bio-pesticide program with a large multinational company – expected by 2024

*<https://www.fao.org/faostat/en/#home>; https://www.nass.usda.gov/Charts_and_Maps/Crops_County/; <https://data.oecd.org/agroutput/crop-production.htm>

**Company estimation

Example Results:

- **Thrivus**™ inoculant for spring wheat
- **LAV 311** bio-fungicide candidates for fruit rot



Lavie Bio's wheat field in the USA during harvest –

Sales initiated in 2022



Example of treatment against *Botrytis Cinerea* vs untreated control in vines

Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement –

Thrivus™

NOVEMBER 3, 2021



Lavie Bio Reports Successful Results for its Bio-Fungicides Programs

FEBRUARY 28, 2023

Mission:

Design next-generation, effective, and sustainable crop protection products by leveraging predictive chemistry and biology

Products & Pipeline



Herbicides

- Novel Mode-of-Action selective herbicide
- Herbicides addressable market – \$48.9B (2027)*



Fungicides

- Novel Mode-of-Action wheat blotch fungicide
- Fungicides addressable market – \$25.81B**



Insecticides

- Novel Site-of-Action resistance breaking piercing/sucking insecticide
- Insecticides addressable market – \$22B (2030)***

* <https://www.statista.com/statistics/1350387/herbicides-market-size-globally/>
 ** <https://www.fortunebusinessinsights.com/fungicides-market-103267>
 *** <https://straitresearch.com/report/insecticides-market>

Expected near-term value drivers

Herbicides

- Milestone achievement of the ongoing collaboration with Corteva
- Engage in a new additional strategic collaboration

Fungicides


- Nominate new Mode-of-Action protein targets
- Initial greenhouse readouts of designed compounds on the defined fungi targets

Platform

- Verification of computational tool for selection of novel Mode-of-Action protein targets
- POC for the computational tool for novel molecule design

Example Results:

New MoA Herbicide – **APH1**



Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1



Greenhouse testing of APH1 – Conferring resistance by modifying tobacco

AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program

DECEMBER 15, 2020

AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate

JULY 6, 2021

Mission:

Provide tailored medical cannabis products to optimize consumer wellbeing.

Products & Pipeline

High Cannabinoid and metabolite content



- The '**G-nnovation**' Series (1st generation)
18-19% THC, launched in Oct 2021
- The '**High-bred**' Series (2nd generation)
23-24% THC and rich terpene profiles, launched in Oct 2022
- Total cannabis market size expected by 2027 – \$82.3B*



The '**Precise**' Series focus on medical indications

- Pain management
- Reduced Inflammation

Expected near-term value drivers

Direct Sales

- Increased revenues from the 2nd generation products during 2023
- Launch of 3rd generation products with high THC levels, specific terpene profiles and unique characteristics, towards end of 2023

New revenue streams

- Commence joint production of Canonic's varieties with a 3rd party based on cost and revenue sharing
- Royalties from licensing of Canonic's varieties

*<https://www.marketsandmarkets.com/Market-Reports/cannabis-market-201768301.html#:~:text=The%20global%20cannabis%20market%20in,of%20whirl%20of%20legalization%20globally.>

The 'high-bred' series 2nd generation products, examples

Synergy inflorescence

T20/C4 Sativa

Top Characteristics

- **24% THC**
- High Level of b-Myrcene
- Genetic Similarity to the 'Super Lemon Haze' variety



Mash Kush inflorescence

T20/C4 Indica

Top Characteristics

- **24.4% THC**
- High Level of Terpinolene
- Genetic Similarity to the 'Headband' variety



Canonic Successfully Launched Six Second-Generation Cannabis Products with Higher THC and Rich Terpene Profiles

FEBRUARY 21, 2023

Plantis Licenses Two of Canonic's Proprietary Cannabis Varieties to Expand its Offerings in the Israeli Market

MAY 2, 2023

Mission:

Leading the castor oil market with an integrated solution for industrialized cultivation of castor in support of the biobased materials industry

Product & Pipeline

Elite castor seed varieties



- 'EVF' series - castor seed suitable for various environmental and climatic conditions
- Estimated addressable castor oil market \$1.21B (2021) and is expected to expand at CAGR of 5.8% from 2022 to 2030*
- Main target markets:
 - **Bio-polymers** – driven by the need for quality and consistent inputs
 - **Bio-fuel** – driven by environmental & regulatory trends in EU



Agro-technical support

- Cultivation protocols to maximize the results of the elite seeds



Dedicated machinery

- Best-in-class harvesting header, developed with Fantini Srl, Italy
- Casterra proprietary patented dehulling machine

* <https://www.grandviewresearch.com/industry-analysis/castor-oil-derivatives-industry>

Expected near-term value drivers

Seeds development

- **Production** – extending production outreach in the target markets: Africa (Zambia), Latin America (Brazil) with few hundred tons a year as of 2024
- **R&D** – development of new seed traits matching industry needs (e.g., Ricin free, low viscosity) using advanced technologies: CRISPR, genetic markers

Territorial expansion

- **Africa** - engaging with bio-fuel strategic industry leaders to increase our sales and sector footprint
- **Latin America** – addressing the bio-polymer industry's interest in broad, consistent and high-quality castor oil supply in Latin America

Strategic alliance

- A strategic alliance with a leading global biofuel company, leveraging Casterra's holistic industrial solution

High yield & oil castor seeds

Elite castor seed varieties – The 'EVF' series



EVF701



EVF712



EVF716

Dedicated machinery



Castor growth protocol



Mechanical Harvest



Proprietary dehulling machine

Casterra Signs Royalty Agreement with Titan for Castor Oil Sales in South-Eastern Africa

NOVEMBER 15, 2022

Casterra Announces Agreement with World Leading Energy Company to Cultivate its Castor Varieties at Commercial Scale

JANUARY 19, 2023

In The News




BIOMICA



lavie bio



agPlenus



casterra



CANONIX


evogene

DECODING BIOLOGY 31

Agenda

- ✦ About Evogene
- ✦ Business model
- ✦ Product-oriented subsidiaries
- ✦ **Summary**

Annex I - Financial Fundamentals



The Evogene Group



134
Employees



27 %
PhDs



51 %
Women

**Incl. chairperson
of the board**

Computational systems biology
Computational chemistry
Bioinformatics Molecular biology
Microbiology Genetics Biochemistry

As of April 30, 2023

Summary

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies

Strong computational predictive biology (CPB) platform
leveraging synergies between a deep understanding of biology, Big Data and AI

Three dedicated **Technology Engines** for discovery & development:

- MicroBoost AI – for products based on microbes
- ChemPass AI – for products based on small-molecules
- GeneRator AI – for products based on genetic elements

Dual based business model via subsidiaries and collaborations

Market-orientated subsidiaries generating value

- Biomica – Human-microbiome based therapeutics
- Lavie Bio – Ag-biologicals
- AgPlenus – Ag-chemicals
- Casterra – Castor growth end-to-end solution
- Canonic – Medical cannabis

A vote of confidence in Evogene's subsidiaries through equity investment by strategic and financial investors:

Lavie Bio – Corteva & ICL

Biomica – SHC

Significant catalysts expected in the coming quarters

A hand is shown holding a glowing blue ring. From the ring, numerous rays of light, composed of binary code (0s and 1s), emanate outwards, creating a starburst effect. The background is a gradient of blue and purple, with a blurred image of a person's face on the right side.

THANK YOU!

evogene
DECODING BIOLOGY



Annex I: Financial Fundamentals

Key Financials: Balance Sheet

Key Points:

- Consolidated cash position: ~\$29 million as of 31.03.2023
- This Consolidated cash position does not include the \$10M Biomica received from the SHC investment in April 2023
- No bank debt
- Listed on TASE (2007) and NASDAQ (2016)

Thousands of US \$	31.03.2023	31.12.2022
Current Assets	31,409	37,751
Long-Term Assets	18,066	18,375
Total Assets	49,475	56,126
Current Liabilities	5,356	5,625
Long-Term Liabilities (inc. \$10m convertible SAFE at Lavie Bio)	15,624	15,711
Equity attributable to equity holders of the Company	22,089	27,930
Non-controlling interest	6,406	6,860
Total Liabilities & Shareholders Equity	49,475	56,126